Autoimmune disease companies develop therapies, diagnostics and research technologies for conditions in which the immune system attacks the body’s own cells and tissues. Their work spans disease detection, immune modulation and the development of more targeted treatments.
This category includes companies working on:
Browse 58 UK autoimmune disease companies below.
ADC oncology company developing novel spliceosome-modulating payloads
Akari Therapeutics is a clinical-stage biopharma company developing next-generation bi-functional antibody-drug conjugates for cancer treatment. Its proprietary ADC platform…
CAR-T and bispecific antibody therapies for blood cancers
Hemogenyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for haematological malignancies and autoimmune diseases. Its lead asset,…
Engineered hybrid interferon therapeutics for viral and immune-mediated disease
ILC Therapeutics is a pre-clinical biotechnology company developing hybrid interferons, an engineered cytokine drug class combining favourable attributes of multiple naturally…
Long-acting eye-drop matrix technology for chronic ocular surface disease
Healome Therapeutics is a University of Birmingham spin-out developing a proprietary eye-drop matrix technology that improves drug retention, lubrication and healing on the eye…
In vivo immune cell reprogramming for autoimmune and inflammatory disease
Flip Therapeutics is a biotechnology company developing in vivo immune cell engineering therapies for chronic autoimmune and inflammatory diseases, including multiple sclerosis,…
GPCR-targeting ophthalmic therapeutics for dry eye and corneal pain
OKYO Pharma is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and chronic ocular pain. Its lead candidate, urcosimod, is a…
GPCR-targeted small molecule therapeutics
Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate G protein-coupled…
Small molecule drug discovery platform focused on immuno-inflammation
C4X Discovery (C4XD) is a UK drug discovery company developing small molecule drug candidates using its proprietary computational and structural chemistry platform. It applies…
Engineered T-regulatory cell therapies for immune-mediated diseases
Quell Therapeutics is a clinical-stage UK biotech developing engineered T-regulatory (Treg) cell therapies for immune-mediated diseases, using its proprietary technology to…
3D multi-omics platform for genetically validated drug target discovery
Enhanced Genomics is a biotechnology company developing a proprietary 3D multi-omics platform that maps genome-wide chromatin interactions to identify genetically validated drug…
Human skin explant CRO for immunotoxicity and drug safety testing
Alcyomics is a contract research organisation providing non-animal, human-based in vitro safety and efficacy testing services to pharmaceutical, biotechnology, and cosmetics…
Antibody therapies depleting pathogenic T cells for autoimmune disease cure
Re-Aim Therapeutics is a biotechnology company developing antibody-based therapies designed to achieve functional cures for T cell-mediated autoimmune diseases. The company's…